Two of the most dreaded illnesses in the world are Ebola and Marburg. The names for these syndromes involves some medical geography; in the first case, a river in Uganda (the Ebola) and in the second, a city in Germany (Marburg), where each of these hemorrhagic fevers was first detected in human patients.
What is a hemorrhagic fever?
Hemorrhagic diseases are, by definition, characterized by profuse bleeding, internally or externally, and often both ways, and both Ebola and Marburg certainly qualify, although the panoply of other accompanying signs varies. (For a complete roster of possible symptoms, see Pittalis et al 2009 below ) Both Ebola and Marburg, are, however, in the early stages, primarily characterized by fever, exhaustion, and confusion in the patient. The hemorrhagic aspect is more obvious only in later stages. Patients may develop dark-blister-like growths on their face and body where blood has pooled from broken capillaries. They may then begin bleeding from the mouth, eyes, or ears. They almost always develop breakdowns in coagulation that leads to multiple sites of internal bleeding in a number of organs, leading further to localized tissue destruction. Eventually, the overall loss of sufficient internal blood supply can lead to shock and death. Fortunately for the patients suffering, they often die only after they have gone into a coma.
How lethal are these two diseases?
While there are some less deadly strains (“Sudan” and “Bundibugyo” see Gupta et al 2010 below), Ebola and Marburg kill off as high as 90% of infected patients, usually within three weeks of their contracting the responsible virus. The remaining patients of course, recover, although it is not always certain why they did so, when so many others have died.
From where did these diseases come?
They really both come from Africa, and all major outbreaks, and most individual cases, almost always are found there only, except for patients traveling to more developed countries seeking diagnosis or treatment, and medical researchers working with the virus in western countries. In addition to Uganda, Ebola has primarily broken out in Gabon, Sudan, and the Congo, with isolated cases elsewhere, including South Africa. That Marburg is connected with a town in Germany has to do with laboratories there that make vaccines. (Two other European outbreaks are based on similar circumstances.) Lab workers in Marburg had routinely been importing African green monkeys, but eventually unawares took in an infected shipment which gave this new disease to their handlers and research scientists. Natural, as opposed to laboratory, outbreaks of Marburg have occurred primarily in Angola, Congo, Kenya, South Africa and Zimbabwe.
If this disease is so deadly, why hasn’t it already wiped out large portions of sub-Saharan Africa?
The disease breaks out most often in very isolated parts of the particular countries involved. There tends to be a steeply rising number of local cases for several weeks to a few months, with a corresponding crescendo of deaths, and then a tapering off, with higher survival rates among later contractors of the virus. It is absolutely clear that quarantining patients and observing extreme measures to protect health providers, other patients and any family visitors, from contact with infective fluids, etc. is prudent and has done much to restrain the spread of outbreaks. But Ebola and Marburg, often disappear altogether from a region as suddenly and unexpectedly as they erupted.
Avoidance of Ebola and Marburg is much like avoiding running out of doors when there is a lightning storm. It’s a very good idea, but of itself does not confer immunity. Avoidance does not seem to protect you from getting the disease unexpectedly elsewhere in sub-Saharan Africa, any more than avoiding one place where lightning has struck in the past will confer immunity to thunderbolts should a storm break out elsewhere and you get caught there by surprise.
Where does the disease lurk, then, between outbreaks?
There is little doubt that these diseases persist in wild animals, where they do not necessarily make all of their natural hosts fatally sick. Rodents, bats, and various small monkeys have been implicated as natural reservoirs (See for example Leroy et al 2009 below). By contrast, chimpanzees and gorillas are known to contract Marburg and Ebola, but seem to die off very quickly much like humans do in response to infection, so they do not seem to be a likely vector, except when their dead carcasses are eaten as bush meat by native peoples. (See Bermejo et al. 2006 below). But those animals which do survive and harbor the virus, in their feces, urine, saliva, blood, and perhaps other body parts or fluids apparently contaminate the food, water, or air that is taken in by nearby humans. While vermin eradication, particularly of rodents, is recommended as a possible preventive strategy to reduce the chances of a community developing an outbreak of Ebola or Marburg, there is not a great deal of evidence that reintroduction of vermin predators (such as the revival of cat ownership which had the effect of reducing rats with bubonic plague carrying fleas) or even chemical extermination of pests has stopped an ongoing outbreak, quite possibly because, with few exceptions, (such as an Angolan episode of Marburg) they tend to be short term any way. Current laboratory experiments in search of effective therapies generally use infected lab mice, rats, guinea pigs, or monkeys. Some of these experimental animals are more disease tolerant than others, and the point of using them is to see what contributes to that tolerance. Other laboratory animals are designed to get sick and die pretty much as a model for the human experience of these diseases. There is a peculiar case in the Philippines where a variant of Ebola called Ebola-Reston (after Reston, Virginia, where a shipment of crab-eating monkeys sent to a medical research lab was found to have Ebola) has infected pigs and pig farmers near Manila, but the pigs seem not to die off quickly, and the farmers do not get sick at all, despite the fact that blood tests show that both animals and men have definitely had some sort of immune reaction indicating some level of infection (See Normile 2009 below).
What currently can be done for patients?
Patients are typically placed in medical isolation wards whenever possible, and given comfort care. They have fluid replacement, pain and fever reducers, but often do not get whole blood transfusions because these simply bleed out so rapidly.
What do we know about the viruses responsible for Ebola and Marburg ?
The structure of both Ebola and Marburg viruses has been very well studied (See, for example, Hartman, Tower & Nichol 2010 or Noda et al 2010 below ) and they are virtually identical, although they trigger slightly different immunological responses and have slightly different means of attacking cells (See Valmas et al 2010 below). These viruses consist of a surprisingly long (for a virus) strand of RNA coated largely with lipids, with fairly short protein prongs alongside. We can detect when and how they begin to penetrate cells (See Lipkin, Paacio & Briese 2009 or Tscherne, Manicassamy & Garcia-Sastre 2010 below ) and can now visualize how these viruses bud (See Liu et al 2010, Mateo et al 2010 and Welsch et al 2010 below). We have a pretty good idea of how they evade the body’s immune defenses (See Basler & Amarasinghe 2009 and Mohamadzadeh 2009 below ) yet provoke fevers that should otherwise have helped kill them off nonetheless (See Okumura et al 2010 below), even as they induce immune cell death (See Bradfute et al 2010 below).
What are the current strategies for fighting Ebola and Marburg?
Vaccines seem to be the route of choice (See Bausch et al 2008 , Geisbert et al 2009, and Olinger et al 2009 below), in part because it does seem that the small percentage of survivors of Ebola and Marburg have developed some immunological means of fighting off the remnant viruses (See Wauquier et al 2009 below) and this suggests that the right antigen triggers will generate a survival response similar to that of these patients. Nonetheless the Food and Drug Administration has relaxed the strict rules for claims of efficacy in humans by allowing initially for a greater reliance on animal models, largely because typical Ebola (and Marburg) outbreaks are extremely unpredictable and very often short-lived and most often happen in poorly equipped remote jungle areas where the numbers of patients fluctuate wildly and setting up rigid double-blind trials is simply unworkable (See Sullivan et al 2009 below).
Some vaccine prototypes are based on evoking natural immune responses to natural Ebola strains or chemically altered Ebola mutants whose ability to replicate wildly and endanger the patient has been tamed (See Halfmann et al 2009 and Prins et al 2010 below), although using specially tailored viruses more commonly associated with the common cold or flu also seems promising (See Bukreyev et al 2010 and Pratt et al 2010 below ).
Attacking proteins necessary for cellular invasion and/or replication is a common theme (See Hood et al 2010 below), as is disrupting RNAs making proteins using antisense morpholino oligomers (See Swenson et al 2009 below) or microencapsulated “small interfering” RNA (Geisbert et al 2010) both of which block off key sites, while other approaches basically allow the viruses to enter some cells but then trap them there by halting the budding process (See Harty 2009 below).
Nightmare scenarios: Weaponization of Marburg and Ebola by the Soviets and reported attempts by terrorists to acquire it
Several websites, including that of the highly respected Federation of American Scientists (https://www.fas.org/programs/bio/factsheets/ebola.html ) give credence to the notion that some form of the Ebola virus was developed as biological weapon of mass destruction by the Soviets, and a book coauthored by a former Soviet bioweapons expert, Ken Alibek (see Alibek & Handelman 1999 below) who is currently a well-respected U.S. based bioterrorism medical expert (see Weinstein & Alibek 2003 below ) also documents the use of the Marburg virus in a similar context. Other credible websites assert that terrorists and doomsday religious cults, most notably the Japanese group Aum Shinrikyo (https://www.globalsecurity.org/wmd/intro/bio_ebola.htm ) have sought to acquire and exploit hemorrhagic viruses. (They instead, released Sarin gas in an attack on the Tokyo subway system, killing 13, wounding 50, and temporarily blinding thousands.) Preparation for medical responses to the use of Ebola and Marburg in terrorist attacks is, alas, not taken as a matter of science fiction or television action and adventure thriller episodes any longer (see DuPuy & Schmaljohn 2009 and Goffman 2010 below).
Tony Stankus, FSLA, email@example.com Professor, Life Sciences Librarian, and Science Coordinator
University of Arkansas Libraries MULN 223 E
365 North McIlroy Avenue
Fayetteville AR 72701-4002
Alibek, Ken, and Stephen Handelman. 1999. Biohazard: the chilling true story of the largest covert biological weapons program in the world, told from the inside by the man who ran it. New York: Random House.
Aman, M. J., Michael S. Kinch, Kelly Warfield, Travis Warren, Abdul Yunus, Sven Enterlein, Eric Stavale, et al. 2009. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Research 83, (3) (09): 245-51.
Barrette, Roger W., Samia A. Metwally, Jessica M. Rowland, Lizhe Xu, Sherif R. Zaki, Stuart T. Nichol, Pierre E. Rollin, et al. 2009. Discovery of swine as a host for the Reston Ebolavirus. Science 325, (5937) (07/10): 204-6.
Basler, Christopher F., and Gaya K. Amarasinghe. 2009. Evasion of interferon responses by Ebola and Marburg viruses. Journal of Interferon & Cytokine Research 29, (9) (09): 511-20.
Bausch, D.G., A/G. Sprecher, B. Jeffs & P. Boumandouki. 2008. Treatment of Marburg and Ebola hemorrhagic fevers: A strategy for testing new drugs and vaccines under outbreak conditions. Antiviral Research 78 (1): 150-60.
Bermejo, M. J.D. Rodrieguez-Teijero, G. Illera, A. Barroso, C. Villa, & P.D. Walsh. 2006. Ebola outbreak kills 5,000 gorillas. Science 314: 1564.
Bhattacharyya, Suchita, Kelly L. Warfield, Gordon Ruthel, Sina Bavari, M. J. Aman, and Thomas J. Hope. 2010. Ebola virus uses clathrin-mediated endocytosis as an entry pathway. Virology 401, (1) (05/25): 18-28.
Bradfute, Steven B., Paul E. Swanson, Mark A. Smith, Eizo Watanabe, Jonathan E. McDunn, Richard S. Hotchkiss, and Sina Bavari. 2010. Mechanisms and consequences of Ebolavirus-induced lymphocyte apoptosis. Journal of Immunology 184, (1) (01/01): 327-35.
Bukreyev, Alexander A., Joshua M. Dinapoli, Lijuan Yang, Brian R. Murphy, and Peter L. Collins. 2010. Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic. Virology 399, (2) (04/10): 290-8.
Dias, M. B., Leonardo Reyes-Gonzalez, Francisco M. Veloso, and Elizabeth A. Casman. 2010. Effects of the USA Patriot Act and the 2002 Bioterrorism Preparedness Act on select agent research in the United States. Proceedings of the National Academy of Sciences of the United States of America 107, (21) (05/25): 9556-61.
Douglas, Janet L., Jean K. Gustin, Kasinath Viswanathan, Mandana Mansouri, Ashlee V. Moses, and Klaus Früh. 2010. The great escape: Viral strategies to counter BST-2/tetherin. Plos Pathogens 6, (5): e1000913-.
Dupuy, Lesley C., and Connie S. Schmaljohn. 2009. DNA vaccines for biodefense. Expert Review of Vaccines 8, (12) (12): 1739-54.
Ebola Reston virus detected pigs in the Philippines. 2009. Euro Surveillance: Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin 14, (4) (01/29).
Feldmann, Heinz. 2010. Are we any closer to combating Ebola infections? Lancet 375, (9729) (05/29): 1850-2.
Geisbert, Thomas W., Joan B. Geisbert, Anders Leung, Kathleen Daddario-DiCaprio, Lisa E. Hensley, Allen Grolla, and Heinz Feldmann. 2009. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. Journal of Virology 83, (14) (07): 7296-304.
Geisbert, Thomas W., Amy C. H. Lee, Marjorie Robbins, Joan B. Geisbert, Anna N. Honko, Vandana Sood, Joshua C. Johnson, et al. 2010. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: A proof-of-concept study. Lancet 375, (9729) (05/29): 1896-905.
Goffman, Thomas E. 2010. Bioterrorism: What might be walking into the ED? The American Journal of Emergency Medicine 28, (4) (05): 515-8.
Gupta, Manisha, Cynthia S. Goldsmith, Maureen G. Metcalfe, Christina F. Spipopoulou, and Pierre E. Rollin. 2010. Reduced virus replication, proinflammatory cytokine production, and delayed macrophage cell death in human PBMCs infected with the newly discovered Bundibugyo Ebolavirus relative to Zaire Ebolavirus. Virology 402, (1) (06/20): 203-8.
Halfmann, Peter, Hideki Ebihara, Andrea Marzi, Yasuko Hatta, Shinji Watanabe, M. Suresh, Gabriele Neumann, Heinz Feldmann, and Yoshihiro Kawaoka. 2009. Replication-deficient Ebolavirus as a vaccine candidate. Journal of Virology 83, (8) (04): 3810-5.
Hartman, Amy L., Jonathan S. Towner, and Stuart T. Nichol. 2010. Ebola and Marburg hemorrhagic fever. Clinics in Laboratory Medicine 30, (1) (03): 161-77.
Hartshorn, Kevan L. 2010. Role of surfactant protein A and D (SP-A and SP-D) in human antiviral host defense. Frontiers in Bioscience (Scholar Edition) 2, : 527-46.
Harty, R.N. 2009. No exit: Targeting the budding process to inhibit filovirus replication. Antiviral Research 81 (3): 189-97.
Hoenen, T., S. Jung, A. Herwig, A. Groseth, and S. Becker. 2010. Both matrix proteins of Ebola virus contribute to the regulation of viral genome replication and transcription. Virology 403, (1) (07/20): 56-66.
Hood, Chantelle L., Jonathan Abraham, Jeffrey C. Boyington, Kwanyee Leung, Peter D. Kwong, and Gary J. Nabel. 2010. Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: Implications for viral entry and immunogenicity. Journal of Virology 84, (6) (03): 2972-82.
Leroy, Eric M., Alain Epelboin, Vital Mondonge, Xavier Pourrut, Jean-Paul Gonzalez, Jean Muyembe-Tamfum, and Pierre Formenty. 2009. Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne and Zoonotic Diseases (Larchmont, N.Y.) 9, (6) (12): 723-8.
Leung, Daisy W., Dominika Borek, Mina Farahbakhsh, Parameshwaran Ramanan, Jay C. Nix, Tianjiao Wang, Kathleen C. Prins, et al. 2010. Crystallization and preliminary X-ray analysis of Ebola VP35 interferon inhibitory domain mutant proteins. Acta Crystallographica.Section F, Structural Biology and Crystallization Communications 66, (06/01): 689-92.
Leung, Daisy W., Kathleen C. Prins, Dominika M. Borek, Mina Farahbakhsh, JoAnn M. Tufariello, Parameshwaran Ramanan, Jay C. Nix, et al. 2010. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nature Structural & Molecular Biology 17, (2) (02): 165-72.
Lipkin, W. I., Gustavo Palacios, and Thomas Briese. 2009. Diagnostics and discovery in viral hemorrhagic fevers. Annals of the New York Academy of Sciences 1171 Suppl 1, (09): E6-E11.
Liu, Yuliang, Luis Cocka, Atsushi Okumura, Yong-An Zhang, J. O. Sunyer, and Ronald N. Harty. 2010. Conserved motifs within Ebola and Marburg virus VP40 proteins are important for stability, localization, and subsequent budding of virus-like particles. Journal of Virology 84, (5) (03): 2294-303.
Mateo, Mathieu, St Patrick Reid, Lawrence W. Leung, Christopher F. Basler, and Viktor E. Volchkov. 2010. Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling. Journal of Virology 84, (2) (01): 1169-75.
Mohamadzadeh, Mansour. 2009. Potential factors induced by filoviruses that lead to immune supression. Current Molecular Medicine 9, (2) (03): 174-85.
Noda, Takeshi, Kyoji Hagiwara, Hiroshi Sagara, and Yoshihiro Kawaoka. 2010. Characterization of the Ebola virus nucleoprotein-RNA complex. The Journal of General Virology 91, (06): 1478-83.
Normile, Dennis. 2009. Emerging infectious diseases. Scientists puzzle over Ebola-Reston virus in pigs. Science 323, (5913) (01/23): 451-.
Okumura, Atsushi, Paula M. Pitha, Akihiko Yoshimura, and Ronald N. Harty. 2010. Interaction between Ebola virus glycoprotein and host toll-like receptor 4 leads to induction of proinflammatory cytokines and SOCS1. Journal of Virology 84, (1) (01): 27-33.
Olinger Gene G., Julia E. Biggins, Vanessa R. Melanson, Victoria Wahl-Jensen Victoria, Thomas W. Geisbert, and Lisa E. Hensley. 2009. Drug targets in infections with Ebola and Marburg viruses. Infectious Disorders Drug Targets 9, (2) (04): 191-200.
Pittalis, Silvia, Francesco Maria Fusco, Simone Lanini, Carla Nisii, Vincenzo Puro, Francesco Nicola Lauria, and Giuseppe Ippolito. 2009. Case definition for Ebola and Marburg haemorrhagic fevers: A complex challenge for epidemiologists and clinicians. The New Microbiologica: Official Journal of the Italian Society for Medical, Odontoiatric, and Clinical Microbiology (SIMMOC) 32, (4) (10): 359-67.
Pratt, William D., Danher Wang, Donald K. Nichols, Min Luo, Jan Woraratanadharm, John M. Dye, David H. Holman, and John Y. Dong. 2010. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clinical and Vaccine Immunology: CVI 17, (4) (04): 572-81.
Prins, Kathleen C., Sebastien Delpeut, Daisy W. Leung, Olivier Reynard, Valentina A. Volchkova, St Patrick Reid, Parameshwaran Ramanan, et al. 2010. Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs. Journal of Virology 84, (6) (03): 3004-15.
Raabe, Vanessa N., Imaam Mutyaba, Paul Roddy, Julius J. Lutwama, Wenzel Geissler, and Matthias Borchert. 2010. Infection control during filoviral hemorrhagic fever outbreaks: Preferences of community members and health workers in Masindi, Uganda. Transactions of the Royal Society of Tropical Medicine and Hygiene 104, (1) (01): 48-50.
Shedlock, Devon J., Michael A. Bailey, Paul M. Popernack, James M. Cunningham, Dennis R. Burton, and Nancy J. Sullivan. 2010. Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology 401, (2) (06/05): 228-35.
Stanwell-Smith, R. 2009. When nature turns cook: An epidemiological feast: Report of the John Snow Society Pumphandle Lecture 2009, delivered by Dr David Heymann. Public Health 123, (12) (12): 814-6.
Sullivan, Nancy J., Julie E. Martin, Barney S. Graham, and Gary J. Nabel. 2009. Correlates of protective immunity for Ebola vaccines: Implications for regulatory approval by the animal rule. Nature Reviews. Microbiology 7, (5) (05): 393-400.
Swenson, Dana L., Kelly L. Warfield, Travis K. Warren, Candace Lovejoy, Jed N. Hassinger, Gordon Ruthel, Robert E. Blouch, et al. 2009. Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrobial Agents and Chemotherapy 53, (5) (05): 2089-99.
Trombley, Adrienne R., Leslie Wachter, Jeffrey Garrison, Valerie Buckley-Beason, Jordan Jahrling, Lisa E. Hensley, Randal J. Schoepp, et al. 2010. Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses. The American Journal of Tropical Medicine and Hygiene 82, (5) (05): 954-60.
Tscherne, Donna M., Balaji Manicassamy, and Adolfo García-Sastre. 2010. An enzymatic virus-like particle assay for sensitive detection of virus entry. Journal of Virological Methods 163, (2) (02): 336-43.
Urata, Shuzo, and Jiro Yasuda. 2010. Regulation of Marburg virus (MARV) budding by Nedd4.1: A different WW domain of Nedd4.1 is critical for binding to MARV and Ebola virus VP40. The Journal of General Virology 91, (01): 228-34.
Valmas, Charalampos, Melanie N. Grosch, Michael Schümann, Judith Olejnik, Osvaldo Martinez, Sonja M. Best, Verena Krähling, Christopher F. Basler, and Elke Mühlberger. 2010. Marburg virus evades interferon responses by a mechanism distinct from Ebola virus. Plos Pathogens 6, (1): e1000721-.
Wauquier, Nadia, Pierre Becquart, Clélia Gasquet, and Eric M. Leroy. 2009. Immunoglobulin G in Ebola outbreak survivors, Gabon. Emerging Infectious Diseases 15, (7) (07): 1136-7.
Weinstein, Raymond S., and Ken Alibek. 2003. Biological and chemical terrorism: a guide for healthcare providers and first responders. New York: Thieme Medical Pub.
Welsch, Sonja, Larissa Kolesnikova, Verena Krähling, James D. Riches, Stephan Becker, and John A. G. Briggs. 2010. Electron tomography reveals the steps in filovirus budding. Plos Pathogens 6, (4): e1000875-.